Bloomberg: Sanofi in advanced talks to buy Actelion

|About: Actelion Ltd. (ALIOF)|By:, SA News Editor

Sanofi (NYSE:SNY), long suspected of coveting Swiss drugmaker Actelion (OTCPK:ALIOF), is in advanced talks to buy the company and is discussing a takeover price of ~$275/share, Bloomberg reports.

The price may include a contingent value right for Actelion shareholders, which would pay out depending on the future performance of certain pipeline drugs, according to the report.

The potential deal, which would value Actelion at ~$29.6B and follows Johnson & Johnson's reported withdrawal from the bidding, could come as soon as next week.

Subscribe for full text news in your inbox